Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00313482
Recruitment Status : Terminated (Low accrual)
First Posted : April 12, 2006
Last Update Posted : May 11, 2012
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Veeda Oncology

Brief Summary:

This is a Phase II, open-label study in male patients with metastatic HRPC.

Each cycle will be 21 days (3 weeks). Patients will receive the following drugs:

  • Docetaxel 75 mg/m2 IV given over 1 hour on Day 1.
  • Prednisone 5 mg orally twice daily beginning on Day 1 and continuing until disease progression.
  • Sargramostim 250 mcg/m2 SC on Days 2-15 of each cycle. Patients will be evaluated every 4 cycles (12 weeks) for response using RECIST criteria. PSA response will be evaluated according to the National Cancer Institute (NCI) PSA Working Group Criteria. To evaluate the safety of this drug combination, patients will be evaluated at each clinic visit for adverse events. Toxicities will be assessed per National Cancer Institute (NCI) CTCAE Version 3.0.

Those patients achieving stable disease or better will continue therapy. Those patients experiencing progressive disease will be taken off study.

Patients will receive a maximum of 10 cycles of treatment.


Condition or disease Intervention/treatment Phase
Hormone Refractory Prostate Cancer Drug: Sargramostim Drug: Docetaxel Drug: Prednisone Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer
Study Start Date : April 2006
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Sargramostim
    250 mcg/m2 SC days 2-15 of each cycle
    Other Name: Leukine
  • Drug: Docetaxel
    75 mg/m2 IV over 1 hour on Day 1 of each cycle
    Other Name: Taxotere
  • Drug: Prednisone
    5 mg orally BID on Day 1 continuously


Primary Outcome Measures :
  1. To evaluate the effects of the combination of docetaxel/prednisone with sargramostim on progression-free survival in chemotherapy-naïve male patients with hormone-refractory prostate cancer (HRPC). [ Time Frame: unk ]

Secondary Outcome Measures :
  1. To evaluate the response (as demonstrated by PSA and/or measurable disease) to the combination of docetaxel/prednisone with sargramostim. [ Time Frame: unk ]
  2. To evaluate the 1-year and 2-year survival following treatment with the combination of docetaxel/prednisone with sargramostim. [ Time Frame: unk ]
  3. To evaluate the safety of the combination of docetaxel/prednisone with sargramostim. [ Time Frame: unk ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have signed an IRB-approved informed consent.
  2. Patients must be male with histologically confirmed metastatic adenocarcinoma of the prostate with progressive disease, despite androgen deprivation.
  3. Patients must have a history of prior hormone therapy (must fulfill one of the following criteria):

    • Castration and/or luteinizing-hormone releasing hormone (LHRH) agonist
    • Antiandrogen therapy (flutamide, nilutamide, bicalutamide, or cyproterone acetate)
    • Antiandrogen therapy withdrawal
    • Estramustine monotherapy
    • Other hormonal therapy (eg, ketoconazole). Note: Patients must be off ketoconazole at least 1 month. If PSA is decreasing, the patient must demonstrate a rising PSA on at least 2 sequential reading at least 2 weeks apart.
  4. Patients must have a serum testosterone <50 ng/dL (if the patient has not undergone orchiectomy, he must continue primary androgen deprivation with LHRH analogue).
  5. Patient must fulfill one of the following criteria:

    • Patients with measurable disease:

    Patients must have disease progression defined by the RECIST criteria.

    • Patients with no measurable disease:

    Patients with PSA only disease must have an elevated PSA by Consensus Criteria. -OR-

    • Patients with a positive bone scan must also have elevated PSA defined by Consensus Criteria.
  6. Progressive disease (as defined above) must be documented after discontinuation of hormonal therapy.
  7. Patients who are receiving an antiandrogen as part of primary androgen ablation must also demonstrate disease progression following discontinuation of the antiandrogen.
  8. Patients on antiandrogen therapy must discontinue therapy and subsequently demonstrate disease progression (at least 4 weeks since prior flutamide or nilutamide, 8 weeks since prior bicalutamide).
  9. Patients must have discontinued all agents or herbal products known to decrease PSA levels (eg, Megace [megestrol acetate], Saw Palmetto, and PC-SPEC) or any systemic corticosteroid at least 4 weeks prior to enrollment.
  10. Patients must have Karnofsky Performance Status (PS) >60.
  11. Patients must have a life expectancy >3 months.
  12. Patients must be >18 years of age.
  13. Patients may have received prior radiation (except for radiation to the entire pelvis), provided that less than 25% of the bone marrow has been treated, and the patient has recovered from the acute toxic effects of treatment prior to trial enrollment. Irradiation of a symptomatic lesion, or one that may produce disability (eg, unstable femur) prior to study initiation is permitted, provided other measurable disease is present. Prior radiation treatment must have been completed at least 4 weeks prior to enrollment. Lesions that have been irradiated in the advanced disease setting may not be included as sites of measurable disease.
  14. Patients must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter.
  15. Patients must have absolute neutrophil count (ANC) >1500/μL, platelet count >100,000/μL, and hemoglobin >8 mg/dL.
  16. Patients must have alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin within normal limits (WNL), serum creatinine <1.5 x upper limit of normal (ULN).
  17. Patients must be willing and able to self-administer or have a caregiver who can administer in compliance with the protocol (sargramostim).

Exclusion Criteria:

  1. Prior systemic chemotherapy for the treatment of HRPC, with the exception of estramustine monotherapy.
  2. Prior treatment with ketoconazole, aminoglutethimide, or corticosteroids for the treatment of progressive prostate cancer.
  3. No prior immunotherapy with the exception of routine immunizations.
  4. Myocardial infarction or significant change in anginal pattern within the last 6 months, symptomatic congestive heart failure (New York Heart Association Class III or higher, see Appendix II) or uncontrolled cardiac arrhythmia.
  5. Patients with known HIV-positive status.
  6. Major surgery or radiation therapy <4 weeks prior to enrollment.
  7. Prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.
  8. Patients with a history of severe hypersensitivity reaction to docetaxel, prednisone, sargramostim, yeast-derived products, other drugs formulated with polysorbate 80, or any of the components in these drugs.
  9. Patients with poorly controlled diabetes (fasting blood glucose >250 mg/dL) despite optimization of medical therapy.
  10. Patients with serious uncontrolled intercurrent infections, nonmalignant medical illnesses, or active uncontrolled autoimmune disease. Note: suppressive antibiotic therapy for chronic urinary tract infections is allowed.
  11. Patients with a systemic fungal infection.
  12. Patients with psychiatric illness/social situations that would limit compliance with treatment or adequate informed consent.
  13. Any patient who is unable to comply with requirements of study.
  14. Patients with symptomatic peripheral neuropathy Grade >2 (NCI Common Toxicity Criteria Version 3.0.
  15. Patients with known brain or leptomeningeal involvement.
  16. Patients with second primary malignancy, except adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated >5 years previously and with no other evidence of recurrence.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00313482


Locations
Layout table for location information
United States, Ohio
Veeda Oncology
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Veeda Oncology
Bayer
Investigators
Layout table for investigator information
Principal Investigator: Evan R Berger, MD North Shore Hematology Oncology Associates

Layout table for additonal information
Responsible Party: Veeda Oncology
ClinicalTrials.gov Identifier: NCT00313482     History of Changes
Other Study ID Numbers: I-05-011
First Posted: April 12, 2006    Key Record Dates
Last Update Posted: May 11, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Prednisone
Docetaxel
Sargramostim
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Immunologic Factors